Evidence map›Paper›PMID 28218395›Full record

ArticleInternational journal of cancer2017

Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.

Saverio Caini, Giovanna Masala, Calogero Saieva, Marina Kvaskoff, Isabelle Savoye, Carlotta Sacerdote, Oskar Hemmingsson, Bodil Hammer Bech, Kim Overvad, Anne Tjønneland and 38 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Daily Lifestyle and Cutaneous Malignancies.International journal of molecular sciences · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Rationale for a Swedish cohort consortium.Upsala journal of medical sciences · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 20 institutions in 12 countries.

Saverio CainiCancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.
Giovanna MasalaCancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.
Calogero SaievaCancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.
Marina KvaskoffCESP, Fac. de médecine-Univ. Paris-Sud, Fac. de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.
Isabelle SavoyeCESP, Fac. de médecine-Univ. Paris-Sud, Fac. de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.
Carlotta SacerdoteUnit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital-University of Turin and Center for Cancer Prevention (CPO), Turin, Italy.
Oskar HemmingssonDepartment of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
Bodil Hammer BechDepartment of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
Kim OvervadDepartment of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
Anne TjønnelandDanish Cancer Society Research Center, Unit of Diet, Genes and Environment, Copenhagen, Denmark.
Kristina E N PetersenDanish Cancer Society Research Center, Unit of Diet, Genes and Environment, Copenhagen, Denmark.
Francesca Romana ManciniCESP, Fac. de médecine-Univ. Paris-Sud, Fac. de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.
Marie-Christine Boutron-RuaultCESP, Fac. de médecine-Univ. Paris-Sud, Fac. de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.
Iris CervenkaCESP, Fac. de médecine-Univ. Paris-Sud, Fac. de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tilman KühnDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany.
Anna FloegelDepartment of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Elisavet ValanouHellenic Health Foundation, Athens, Greece.
Maria KritikouHellenic Health Foundation, Athens, Greece.
Giovanna TagliabueLombardy Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Salvatore PanicoDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Rosario TuminoCancer Registry and Histopathology Unit, "Civic-M.P.Arezzo" Hospital, ASP, Ragusa, Italy.
H B As Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases, National Institute for Public Health and the Envirnoment (RIVM), Bilthoven, The Netherlands.
Petra H PeetersDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.
Marit B VeierødOslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway.
Reza GhiasvandOslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway.
Marko LukicDepartment of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
José Ramón QuirósPublic Health Directorate, Asturias, Oviedo, Spain.
Maria-Dolores ChirlaqueDepartment of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Eva ArdanazCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Elena Salamanca FernándezCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Nerea LarrañagaCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Raul Zamora-RosUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology (ICO), Barcelona, Spain.
Lena Maria NilssonDepartment of Public Health and Clinical Medicine, Nutritional research and Arcum-Arctic Research Centre, Umeå University, Umeå, Sweden.
Ingrid LjuslinderDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Karin JirströmDepartment of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden.
Emily SonestedtDepartment of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Nick WarehamMRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
Kay-Tee KhawUniversity of Cambridge, Cambridge, United Kingdom.
Marc GunterSection of Nutrition and Metabolism, International Agency for Research on Cancer (IARC), Lyon, France.
Inge HuybrechtsSection of Nutrition and Metabolism, International Agency for Research on Cancer (IARC), Lyon, France.
Neil MurphyDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Elisabete WeiderpassPublic Health Directorate, Asturias, Oviedo, Spain.
Domenico PalliCancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.ORCID http://orcid.org/0000-0002-5558-2437
Université Paris-Sud · FRPiedmont Reference Center for Epidemiology and Cancer Prevention · ITAarhus University · DKCentre international de recherche sur le cancer · FRDanish Cancer Society · DKGerman Cancer Research Center · DEGerman Institute of Human Nutrition · DEGobierno del Principado de Asturias · ESHellenic Health Foundation · GRLund University · SEUmeå University · SEUniversity of Cambridge · GBUniversity of Oslo · NOArctic Research Centre · SEAzienda Usl 8 Arezzo · ITBasque Government · ESFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITImperial College London · GBInstitut d'Investigació Biomédica de Bellvitge · ES

Funding

Cancer Research UK 14136Cancer Research UK 16491Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_UU_12015/1Medical Research Council MR/N003284/1World Health Organization 001
6 · The paper itself

Abstract

In vitro and animal studies suggest that bioactive constituents of coffee and tea may have anticarcinogenic effects against cutaneous melanoma; however, epidemiological evidence is limited to date. We examined the relationships between coffee (total, caffeinated or decaffeinated) and tea consumption and risk of melanoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a multicentre prospective study that enrolled over 500,000 participants aged 25-70 years from ten European countries in 1992-2000. Information on coffee and tea drinking was collected at baseline using validated country-specific dietary questionnaires. We used adjusted Cox proportional hazards regression models to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for the associations between coffee and tea consumption and melanoma risk. Overall, 2,712 melanoma cases were identified during a median follow-up of 14.9 years among 476,160 study participants. Consumption of caffeinated coffee was inversely associated with melanoma risk among men (HR for highest quartile of consumption vs. non-consumers 0.31, 95% CI 0.14-0.69) but not among women (HR 0.96, 95% CI 0.62-1.47). There were no statistically significant associations between consumption of decaffeinated coffee or tea and the risk of melanoma among both men and women. The consumption of caffeinated coffee was inversely associated with melanoma risk among men in this large cohort study. Further investigations are warranted to confirm our findings and clarify the possible role of caffeine and other coffee compounds in reducing the risk of melanoma.

Indexed as

Anticarcinogenic AgentsCoffeeTeaAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasmsPrognosisProspective StudiesRegistriesRisk AssessmentRisk FactorsAnticarcinogenic AgentsCoffeeTeacoffeecohort studymelanomarisktea

Identifiers

PMID28218395
PMCPMC6198927
OpenAlexW2589788277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.